Key clinical point: Navigator-driven outreach helped improve medication adherence in heart failure patients.
Major finding: Beta-blocker adherence in the navigator group improved 14 percentage points from baseline versus 2 points for usual care.
Study details: Single-center cohort of 1,028 patients with HF reduced ejection fraction.
Disclosures: Dr. Desai disclosed financial relationships with Novartis, AstraZeneca, Abbott, Boehringer-Ingelheim, Coston Scientific, Biofourmis, DalCor, Relypsa, Regeneron, and Alnylam. Novartis provided an unrestricted grant to the investigator-initiated trial.
Desai AS et al. AHA 2019, Featured Science session AOS.07.